Interactions between HTLV-1 Tax and NF-kappa B/rel oncoproteins in T cells (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Interactions between HTLV-1 Tax and NF-kappa B/rel oncoproteins in T cells (Meeting abstract).

International Association for Comparative Research on Leukemia and Related Diseases, 16th Symposium. July 11-16, 1993, Montreal, Quebec, Canada, A18, 1993.. Unique Identifier : AIDSLINE ICDB/94698625
Lanoix J; Lacoste J; Pepin N; Le L; Roulston A; Rice N; Hiscott J; Lady Davis Inst., Jewish General Hospital and Dept. of; Microbiology and Immunology, McGill Univ., Montreal H3T 1E2,; Canada


Abstract: Molecular, biochemical and epidemiological evidence strongly implicate HTLV-1 as an etiologic agent of adult T cell leukemia (ATL). The Tax protein of HTLV-1, a positive transcriptional activator of HTLV-1 gene expression is a viral oncogene that also increases transcription of cellular genes. One of the cellular targets of the trans-activating effects of Tax is the NF-kappaB/rel family of transcription factors, pleiotropic regulators of immunoregulatory, cytokine and viral gene expression. The trans-activation of NF-kappaB regulated (GGGACTTTCC) reporter gene activity was measured in co-expression studies using expression vectors for individual NF-kappaB subunits and the Tax protein. Tax behaved as a trans-dominant activator of NF-kappaB regulated reporter plasmid and could overcome the inhibitory effect of I kappaB alpha (MAD3), delta Rel-A(p65delta), a splicing variant of the Rel-A(p65) subunit, and the weakly trans-activating c-Rel protein. Analysis of NF-kappaB proteins in Jurkat T cells, Tax-expressing Jurkat cells (19D), and in HTLV-1 infected MT-2 cells by mobility shift and Western blot analyses with subunit specific antibodies revealed dynamic alterations in NF-kappa B binding activity and in the synthesis of NF-kappa B proteins. As characterized previously by Greene and colleagues, PMA induction of NF-kappa B binding activity in Jurkat cells was biphasic; at 2 hours after treatment, protein-DNA complexes were composed mainly of NFKB1 (p50) and Rel-A(p65) while at 24 hr, c-Rel and NFKB1 (p50) were the main subunits in protein-DNA complexes. In Tax expressing 19D cells, c-Rel and NFKB2(p52 or lyt-10) represented the main DNA binding activities. The correlation between Tax expression and specific NF-kappaB binding proteins was further strengthened with the observation that c-Rel and NFKB2 subunits were the major DNA binding forms in HTLV-1 producing MT-2 cells. Western blot analysis revealed 5- to 10-fold increases in the amounts of Rel-A (p65), c-Rel and NFKB2 (p52) proteins in both Tax-expressing 19D cells and HTLV-1 infected MT-2 cells. These results suggest that interaction of Tax with specific NF-kappa B/rel oncoproteins may be an important event leading to transformation of T cells by HTLV-1.
Keywords: Cell Transformation, Neoplastic DNA, Neoplasm/METABOLISM Gene Products, tax/*METABOLISM Human HTLV-I Infections/METABOLISM NF-kappa B/*METABOLISM Proto-Oncogene Proteins/*METABOLISM RNA Splicing T-Lymphocytes/*METABOLISM/PATHOLOGY ABSTRACTKWDcelltransformation,neoplasticdna,neoplasm/metabolismgeneproducts,tax/KWDmetabolismhumanhtlv-iinfections/metabolismnf-kappab/KWDmetabolismproto-oncogeneproteins/KWDmetabolismrnasplicingt-lymphocytes/KWDmetabolism/pathologyabstract
940730
M9470927

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .